• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Updated Meta-Analysis: Vaginal Progesterone for Preterm Prevention in Women with Twin Pregnancies and Short Cervix

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • Romero et al. (Ultrasound in Obstetrics & Gynecology, 2022) updated the 2017 meta-analysis to assess whether vaginal progesterone was associated with a reduced risk of preterm birth in women with twin pregnancies and short cervix 

METHODS: 

  • Individual patient data meta-analysis 
  • Study inclusion criteria 
    • RCTs published from 2017 to 2021 
    • Studies that compared vaginal progesterone (any dose) vs placebo/no treatment for the prevention of preterm birth and/or adverse perinatal outcome in women with a twin gestation and a mid-trimester sonographic cervical length ≤25 mm 
  • Study design 
    • Update of a 2017 
      • 1 study removed due to lack of prior approval by ethics committee 
      • Inclusion of 1 new research study  
    • Risk of bias in included studies was assessed with criteria recommended by the Cochrane Handbook for Systematic Reviews of Interventions 
    • Grade criteria used to assess quality of evidence 
    • Adjusted relative risk (RR) used as main estimates to determine effect of vaginal progesterone on primary outcome 
  • Primary outcome 
    • Preterm birth <33 weeks 
  • Secondary outcomes 
    • Preterm birth < 37, < 36, < 35, < 34, < 32, < 30 and < 28 weeks’ gestation 
    • Spontaneous preterm birth < 33 and < 34 weeks’ gestation 
    • Adverse perinatal outcomes: RDS | NEC | IVH | Proven neonatal sepsis | Retinopathy of prematurity | Fetal death | Neonatal death | Perinatal death | Composite outcome of neonatal morbidity and mortality 

RESULTS: 

  • 6 studies (5 from 2017 study and 1 new study) | 90 women | 195 fetuses 
    • All studies were deemed to be at low risk of bias 
  • Vaginal progesterone significantly reduced the risk of preterm birth <33 weeks’ 
    • Vaginal progesterone: 38.5% 
    • Placebo/no treatment: 55.8% 
    • RR 0.60 (95% CI, 0.38 to 0.95); P=0.03 
    • Needed to treat (NNT) for benefit: 5 (95% CI, 3 to 36) 
  • Vaginal progesterone group had significantly lower frequencies of  
    • Preterm birth at < 34, < 32, < 30 and < 28 weeks 
    • Spontaneous preterm birth at < 33 and < 34 weeks 
  • There was no evidence of an effect of vaginal progesterone on preterm birth < 37, < 36 and < 35 weeks’ gestation 
  • Treatment with vaginal progesterone was also associated with a significant decrease in the risk for 
    • Composite neonatal morbidity and mortality 
      • RR 0.59 (95% CI, 0.33 to 0.98) 
    • Birth weight < 1500 g  
      • RR 0.55 (95% CI, 0.33 to 0.94) 

CONCLUSION: 

  • In this updated individual patient data meta-analysis, vaginal progesterone was still associated with a reduced risk of preterm birth in women with twin pregnancy and short cervix 
  • The authors state 

Nevertheless, it should be emphasized that evidence from an ongoing randomized controlled trial (PROSPECT study) is needed to establish whether this promising intervention can be recommended to women with a twin gestation and a short cervix 

Learn More – Primary Sources: 

Vaginal progesterone for the prevention of preterm birth and adverse perinatal outcomes in twin gestations with a short cervix: an updated individual patient data meta-analysis 

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Vaginal Progesterone to Prevent Preterm Birth in Twins
Does Vaginal Progesterone Improve Birth Outcomes for Mothers with Short Cervix?
RCT Results: Does Addition of Pessary to Progesterone Treatment Prevent Preterm Birth in the Setting of Short Cervix?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site